Neurosense Therapeutics Ltd (NRSN) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access NRSN Annual Balance Sheets →
This balance sheet overview for Neurosense Therapeutics Ltd spans from Dec 31 2024 to Dec 31 2025, showing how the company's assets, liabilities, and equity have evolved across reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
0 0 0 (Dec 31 2024)
Assets
Cash & cash equivalent0.17
Restricted Cash and Investments, Current, Total0.05
Cash & Short-term Investments0.00
Other Receivables, Net, Current0.57
Total loans net0.08
Total Current Assets0.78
Equipment/Property/Plant Net0.08
Long-term investments0.02
Tax Assets, Noncurrent10.18
Other Assets, Noncurrent0.02
Total Assets1.03
Liabilities
Accounts Payable, Trade, Current0.80
Accrued Liabilities, Current0.56
Other Liabilities, Current0.00
Total Current Liabilities2.52
Total Long-term Debt0.00
Accrued Income Taxes, Noncurrent0.04
Other liabilities, Noncurrent1.19
Total Liabilities2.59
Stockholders' Equity
Additional Paid In Capital Common Stock46.23
Retained Earnings / Accumulated Deficit-47.79
Other Equity0.00
Common Stockholder's Equity-1.56
Total Stockholder's Equity-1.56
Liabilities & Stockholder's Equity1.03
4 historic quarters locked

Sign in to unlock the full Neurosense Therapeutics Ltd balance sheet history.

About Neurosense Therapeutics Ltd Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001213900-26-036970

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.